top of page
  • Writer's pictureEmerging Technology Insider

Humanoid robot company UBTech debuts on the Hong Kong Stock Exchange and raises US$128 million in IPO

  • UBTech is the first humanoid robot company to go public on HKEx

  • Qiming is UBTech's early institutional investor, exclusively investing in its Series A round in 2015

  • UBTech's listing is Qiming's eighth IPO in 2023


Qiming Venture Partners' portfolio company UBTech, a humanoid robot leader in China, successfully debuted on the Hong Kong Stock Exchange today. The first humanoid robot company to list on the exchange, UBTech (SEHK:9880)'s issue price was HK$90.00 per share, valuing it at HK$37.60 billion.


At the listing ceremony, Panda Robot Youyou took to the stage and presented a mallet to Zhou Jian, Chairman, Executive Director, and CEO of UBTECH. In a pioneering move, Zhou Jian and UBTECH's newest generation of industrial humanoid robot Walker S, holding another mallet, jointly hit the ceremonial gong, which has made a footnote in history and symbolically ushered an era of human-robot synergy. 


As an early institutional investor in UBTech, Qiming has been a key supporter since exclusively investing in its Series A financing in 2015. The successful listing also marks the eighth IPO for Qiming in 2023.


Established in March 2012, UBTech is one of the few market players in the global humanoid robot industry. The company is dedicated to the research and development of humanoid robots, and design, production, and commercialization of smart service robot solutions. Notably, UBTech was among the first to commercialize while the sector was still at a nascent stage.


From 2020 to the first half of 2023, UBTech's R&D expenditures account for an average of 56.5% of total revenue. The company holds over 1,800 registered robotic and AI-related patents as of June 30, 2023, including more than 900 invention patents and over 380 overseas patents. UBTech's full-stack technology combines robotic technologies (robotic motion planning and control technology and servo actuators) and AI technologies (computer vision and voice interaction technologies), powering a range of integrated robotic and AI technologies (SLAM and autonomous technology, visual servo operation, and human-robot interaction), controlled through the self-developed Robot Operating System Application Framework (ROSA).


Leveraging advanced humanoid robot technologies, UBTech offers products and services across five main areas in AI education, smart logistics, smart wellness and elderly care, commercial services, and consumer-level robots. As of December 10, 2023, UBTech has served a broad customer base primarily in China and over 50 other countries and regions globally, with more than 900 corporate clients and over 760,000 units of robotic products sold during its track record period.


"In the field of hard & core technology, it's essential for entrepreneurs to strike a balance between what's technically possible and what the market needs. I am deeply convinced of the substantial and real market need for humanoid robots. Regardless of whether it takes ten or thirty years, we are committed to realizing our goals." Said Zhou Jian, "Therefore, it is crucial for entrepreneurs to collaborate with investors who share a similar vision and focus on fostering long-term value. In this regard, Qiming Venture Partners has made a worthy example."


Duane Kuang, Founding Managing Partner of Qiming Venture Partners, said, "Mr. Zhou's commitment to the humanoid robot industry and his entrepreneurial drive to overcome challenges have impressed us from the start. We are proud to have supported UBTech's journey to the IPO. Qiming is optimistic about the future of AI and humanoid robots, and we are bullish on Chinese entrepreneurs and companies who dare to innovate and break new grounds in these sectors."


About Qiming Venture Partners

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China and Singapore.


Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.


Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.


Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, New Horizon Health, Sanyou Medical, AmoyDx, Berry Genomics, SinocellTech, UBTech, Yuanxin Technology, Caidya, Belief BioMed, WeRide, Biren Technology, among many others.


Qiming Venture Partners

__________________________________________________



What are your company's business or financial objectives?




If your company has business or financial objectives, check out the advisory services for growing global technology companies provided by FC Global Strategies.


FC Global Strategies also sponsors Emerging Technology Insider.


Our calendar link to schedule a complimentary call.


FC Global Strategies' regional directors:


Jeffrey Friedland - Based in the U.S.

(North America and Global)

+1 646 450 8909


Ross Swan - Based in Singapore

(Southeast Asia, Australia, Asia-Pacific)

+65 9181 9472


David Krutonog - Based in Israel

(Eastern Europe, Middle-East and North Africa

+972 50 974 3429


Claudio Hebling - Based in Brazil

(Latin America)

+55 19 99377 748


Vincent Paul Joseph - Based in India

(South Asia, India and Sri Lanka)

+91 962 620 9090


Olah Abiodun - Based in Nigeria

(Sub-Saharan Africa)

+234 812 029 8222

bottom of page